Incysus Therapeutics, Inc. announced that the Company will present an overview of the company and at the upcoming Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case.  The presentation will be Monday, August 10, 2020 at 3:00 p.m. Eastern Time.

Link

Incysus Therapeutics, Inc. announced that the Company will present at the 2020 LifeSci Partners Virtual Summer Symposium on Wednesday, August 5th.  William Ho, President, Chief Executive Officer, and co-founder of Incysus Therapeutics, will present a company update at 2:00 p.m. Eastern Time.

Link

Incysus Therapeutics, Inc. announced that the first patient in a Phase 1 clinical study titled, “Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma” has been treated at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham. Incysus’ Drug Resistant Immunotherapy (DRI) Is the First Genetically Engineered γδ T Cell Therapy to be Administered to a Patient.

Link

Incysus Therapeutics, Inc. announced that data related to the Company’s ongoing Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma will be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Link

Incysus Therapeutics, Inc. announced that the first patient in a Phase 1 clinical study titled, “Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide” has been treated at The University of Kansas Cancer Center (KU Cancer Center).

Link

Incysus Therapeutics, Inc. today announced that the Company the Company will present at the 2020 Solebury Trout Virtual Investor Conference on Tuesday, April 7th at 1:00pm Eastern Time. To access the presentation, please login here

Link

Incysus Therapeutics, Inc. today announced that the Company the Company will present at the 2020 NYC Spring Oncology Investor Conference being held on March 31st and April 1st. William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company update.

Link

Incysus Therapeutics, Inc. today announced that the Company has initiated a Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma.  This trial is being conducted at the University of Alabama at Birmingham (UAB) and is now active and open for enrollment.

Link

Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will present at the 2020 BIO CEO & Investor Conference on Monday, February 10, 2020 at 1:15 p.m. Eastern Time.  The Conference will be held at the New York Marriott Marquis hotel on 1535 Broadway in New York City.

Link

Incysus Therapeutics, Inc. today announced that the USPTO has issued, U.S. Patent Number 10,543,233 titled “Drug Resistant Immunotherapy for Treatment of a Cancer.”  The patent broadly covers the use of genetic engineering to chemo-protect gamma-delta (γδ) T cells and allow simultaneous chemo-immunotherapy combinations for the treatment of cancer.

Link

Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will present at the Biotech Showcase on Monday, January 13, 2020 at 3:15 p.m. Pacific Time in the Franciscan B Ballroom (Ballroom Level).  The conference will be held at the Hilton San Francisco Union Square, San Francisco, CA.

Link